{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:56:25Z","timestamp":1784249785363,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T00:00:00Z","timestamp":1533772800000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002865","name":"National Science Foundation of Chongqing Science and Technology Commission","doi-asserted-by":"publisher","award":["cstc2016jcyjA1406"],"award-info":[{"award-number":["cstc2016jcyjA1406"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jns.2017.07.042","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T23:46:32Z","timestamp":1501199192000},"page":"256-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"380","author":[{"given":"Ting-ting","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-yang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2017.07.042_bb0005","author":"MS Society Australia"},{"issue":"12","key":"10.1016\/j.jns.2017.07.042_bb0010","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2165\/00003495-200464120-00003","article-title":"Management of fatigue in patients with multiple sclerosis","volume":"64","author":"Zifko","year":"2004","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jns.2017.07.042_bb0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/archneur.1996.00550020101021","article-title":"The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis","volume":"53","author":"Geisler","year":"1996","journal-title":"Arch. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2017.07.042_bb0020","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1212\/WNL.45.11.1956","article-title":"Fatigue therapy in multiple sclerosis results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo","volume":"45","author":"Krupp","year":"1995","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2017.07.042_bb0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1017\/S0317167100026603","article-title":"A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group","volume":"14","author":"The Canadian MS Research Group","year":"1987","journal-title":"Can. J. Neurol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.jns.2017.07.042_bb0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2003.11.005","article-title":"Comparison of the effects of acetyl-l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial","volume":"218","author":"Tomassini","year":"2004","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.jns.2017.07.042_bb0035","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1212\/01.WNL.0000158272.27070.6A","article-title":"Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study","volume":"64","author":"Stankoff","year":"2005","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2017.07.042_bb0040","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1352458506069538","article-title":"Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"13","author":"Goodman","year":"2007","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.jns.2017.07.042_bb0045","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00415-009-0152-7","article-title":"Modafinil effects in multiple sclerosis patients with fatigue","volume":"256","author":"Lange","year":"2009","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2017.07.042_bb0050","first-page":"428","article-title":"Does amantadine have favourable effects on fatigue in Persian patients suffering from multiple sclerosis?","volume":"43","author":"Ashtari","year":"2009","journal-title":"Neurol. Neurochir. Pol."},{"issue":"8","key":"10.1016\/j.jns.2017.07.042_bb0055","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1177\/1352458511402410","article-title":"HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis","volume":"17","author":"M\u00f6ller","year":"2011","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.jns.2017.07.042_bb0060","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1179\/1743132812Y.0000000081","article-title":"Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study","volume":"34","author":"Shaygannejad","year":"2012","journal-title":"Neurol. Res."},{"issue":"12","key":"10.1016\/j.jns.2017.07.042_bb0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.clineuro.2013.09.029","article-title":"Evaluating the effects of amantadin, modafinil and acetyl-l-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study","volume":"1","author":"Ledinek","year":"2013","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"7","key":"10.1016\/j.jns.2017.07.042_bb0070","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1212\/01.WNL.0000156803.23698.9A","article-title":"A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis","volume":"64","author":"Wingerchuk","year":"2005","journal-title":"Neurology"},{"issue":"10 Supplement","key":"10.1016\/j.jns.2017.07.042_bb0075","article-title":"Aspirin is unlikely to have a clinically meaningful effect on multiple sclerosis-related fatigue: data from a randomized controlled trial (P7. 245)[J]","volume":"82","author":"Shuster","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2017.07.042_bb0080","doi-asserted-by":"crossref","DOI":"10.1097\/WNF.0000000000000130","article-title":"Changes in cognitive processing speed, mood, and fatigue in an observational study of persons with multiple sclerosis treated with dalfampridine-ER","volume":"39","author":"Triche","year":"2016","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2017.07.042_bb0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clineuro.2015.08.023","article-title":"Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients","volume":"139","author":"Pavsic","year":"2015","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"8","key":"10.1016\/j.jns.2017.07.042_bb0090","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1212\/WNL.42.8.1468","article-title":"A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis","volume":"42","author":"Weinshenker","year":"1992","journal-title":"Neurology"},{"issue":"Suppl 200(S200)","key":"10.1016\/j.jns.2017.07.042_bb0100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/ane.12648","article-title":"Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions","volume":"134","author":"Brenner","year":"2016","journal-title":"Acta Neurol. Scand."},{"issue":"3","key":"10.1016\/j.jns.2017.07.042_bb0105","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1468-1331.2008.02432.x","article-title":"Fatigue, depression and disability accumulation in multiple sclerosis: a cross-sectional study","volume":"16","author":"Koch","year":"2009","journal-title":"Eur. J. Neurol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17304768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17304768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:44:21Z","timestamp":1758383061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X17304768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":20,"alternative-id":["S0022510X17304768"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2017.07.042","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2017.07.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}